| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_62d1b8b0c95dc64dbe7e020d6c97f74f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec7aa9366c4867ba95ac5cd4fbbaec25 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6037
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55544
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55583
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-543 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-095 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-102
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-385
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 |
| filingDate |
2003-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00bed350eae7ca2ff38545b0a097f582
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27a24e1b0ce34795bc926eeb57962d04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf3b2cf9a5d5be06df594ad6cd964ef6 |
| publicationDate |
2005-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1506008-A2 |
| titleOfInvention |
Mucosal vaccines with chitosan adjuvant and/or meningococcal antigens |
| abstract |
The invention provides immunogenic compositions comprising (a) a capsular saccharide antigen from serogroup C of N.meningitidis, and (b) a chitosan adjuvant. The composition preferably comprises (c) one or more further antigens and/or (d) one or more further adjuvants. The compositions are particularly suitable for mucosal delivery, including intranasal delivery. The invention also provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of N.meningitidis. It is preferred that the capsular saccharides in the compositions of the invention are conjugated to carrier protein(s) and/or are oligosaccharides. Conjugated oligosaccharide antigens are particularly preferred. |
| priorityDate |
2002-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |